Ibrutinib and idelalisib block immunophenotypic changes associated with the adhesion and activation of CLL cells in the tumor microenvironment

References

• Burger JA. The CLL cell microenvironment. Adv Exp Med Biol. 2013;792:25–45.
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Bertilaccio MT, Scielzo C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin Cancer Biol. 2014;24:43–48.
   PubMed Web of Science ®Google Scholar
• Ghia P, Chiorazzi N, Stamatopoulos K. Microenviron-mental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. J Intern Med. 2008;264:549–562.
   PubMed Web of Science ®Google Scholar
• Lagneaux L, Delforge A, Bron D, et al. Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood. 1998;91:2387–2396.
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Jones D, Ganeshaguru K, et al. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996;92:97–103.
   PubMed Web of Science ®Google Scholar
• Ghia P, Circosta P, Scielzo C, et al. Differential effects on CLL cell survival exerted by different microenvironmental elements. Curr Top Microbiol Immunol. 2005;294:135–145.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Burger JA, Tsukada N, Burger M, et al. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood. 2000;96:2655–2663.
   PubMed Web of Science ®Google Scholar
• Buske C, Gogowski G, Schreiber K, et al. Stimulation of B-chronic lymphocytic leukemia cells by murine fibroblasts, IL-4, anti-CD40 antibodies, and the soluble CD40 ligand. Exp Hematol. 1997;25:329–337.
   PubMed Web of Science ®Google Scholar
• Buske C, Twiling A, Gogowski G, et al. In vitro activation of low-grade non-Hodgkin’s lymphoma by murine fibroblasts, IL-4, anti-CD40 antibodies and the soluble CD40 ligand. Leukemia. 1997;11:1862–1867.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–2506.
   PubMed Web of Science ®Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–3397.
   PubMed Web of Science ®Google Scholar
• Herman SE, Mustafa RZ, Jones J, et al. Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin Cancer Res. 2015;21:4642–4651.
   PubMed Web of Science ®Google Scholar
• de Rooij MF, Kuil A, Geest CR, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–2594.
   PubMed Web of Science ®Google Scholar
• de Rooij MF, Kuil A, Kater AP, et al. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125:2306–2309.
   PubMed Web of Science ®Google Scholar
• Huang PY, Best OG, Almazi JG, et al. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma. 2014;55:2085–2092.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446–5456.
   PubMed Web of Science ®Google Scholar
• Ponader S, Chen SS, Buggy JJ, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–1189.
   PubMed Web of Science ®Google Scholar
• Mruk DD, Cheng CY. Enhanced chemiluminescence (ECL) for routine immunoblotting: an inexpensive alternative to commercially available kits. Spermatogenesis. 2011;1:121–122.
   PubMedGoogle Scholar
• Benjamini Y, Drai D, Elmer G, et al. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 2001;125:279–284.
   PubMed Web of Science ®Google Scholar
• Yellin MJ, Sinning J, Covey LR, et al. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol. 1994;153:666–674.
   PubMed Web of Science ®Google Scholar
• Romano C, De Fanis U, Sellitto A, et al. Effects of preactivated autologous T lymphocytes on CD80, CD86 and CD95 expression by chronic lymphocytic leukemia B cells. Leuk Lymphoma. 2003;44:1963–1971.
   PubMed Web of Science ®Google Scholar
• Punnonen J, Cocks BG, Carballido JM, et al. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med. 1997;185:993–1004.
   PubMed Web of Science ®Google Scholar
• Liu FT, Jia L, Wang P, et al. CD126 and targeted therapy with tocilizumab in chronic lymphocytic leukemia. Clin Cancer Res. 2016;22:2462–2469.
   PubMed Web of Science ®Google Scholar
• Romero X, Zapater N, Calvo M, et al. CD229 (Ly9) lymphocyte cell surface receptor interacts homophilically through its N-terminal domain and relocalizes to the immunological synapse. J Immunol. 2005;174:7033–7042.
   PubMed Web of Science ®Google Scholar
• Hock BD, Fernyhough LJ, Gough SM, et al. Release and clinical significance of soluble CD83 in chronic lymphocytic leukemia. Leuk Res. 2009;33:1089–1095.
   PubMed Web of Science ®Google Scholar
• Hulkkonen J, Vilpo L, Hurme M, et al. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia. 2002;16:178–185.
   PubMed Web of Science ®Google Scholar
• Davids MS, Letai A, Brown JR. Overcoming stroma-mediated treatment resistance in chronic lymphocytic leukemia through BCL-2 inhibition. Leuk Lymphoma. 2013;54:1823–1825.
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Gibellini F, Njuguna N, et al. CD44 signaling via PI3K/AKT and MAPK/ERK pathways protects CLL cells from spontaneous and drug induced apoptosis through MCL-1. Leuk Lymphoma. 2011;52:1758–1769.
   PubMed Web of Science ®Google Scholar
• Belov L, de la Vega O, dos Remedios CG, et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001;61:4483–4489.
   PubMed Web of Science ®Google Scholar
• Belov L, Huang P, Chrisp JS, et al. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J Immunol Methods. 2005;305:10–19.
   PubMed Web of Science ®Google Scholar
• Willimott S, Baou M, Huf S, et al. Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. Haematologica. 2007;92:1359–1366.
   PubMed Web of Science ®Google Scholar
• Kitada S, Zapata JM, Andreeff M, et al. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1999;106:995–1004.
   PubMed Web of Science ®Google Scholar
• Arva E, Andersson B. Kinetics of cytokine release and expression of lymphocyte cell-surface activation markers after in vitro stimulation of human peripheral blood mononuclear cells with Streptococcus pneumoniae. Scand J Immunol. 1999;49:237–243.
   PubMed Web of Science ®Google Scholar
• Smilevska T, Stamatopoulos K, Samara M, et al. Transferrin receptor-1 and 2 expression in chronic lymphocytic leukemia. Leuk Res. 2006;30:183–189.
   PubMed Web of Science ®Google Scholar
• Purroy N, Abrisqueta P, Carabia J, et al. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget. 2015;6:7632–7643.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
   PubMed Web of Science ®Google Scholar
• Parmar S, Patel K, Pinilla-Ibarz J. Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia. P T. 2014;39:483–519.
   PubMedGoogle Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011;117:591–594.
   PubMed Web of Science ®Google Scholar
• Wei YY, Zhang XZ, Zhang F, et al. [Expression of CD71 on cell proliferation in hematologic malignancy and its correlation with Ki-67]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015;23:234–240.
   PubMedGoogle Scholar
• Herman SE, Sun X, McAuley EM, et al. Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27:2311–2321.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Qi H, Lu KT, et al. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity. 2010;32:253–265.
   PubMed Web of Science ®Google Scholar
• Binsky-Ehrenreich I, Marom A, Sobotta MC, et al. CD84 is a survival receptor for CLL cells. Oncogene. 2014;33:1006–1016.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078–2088.
   PubMed Web of Science ®Google Scholar
• Yunta M, Lazo PA. Apoptosis protection and survival signal by the CD53 tetraspanin antigen. Oncogene. 2003;22:1219–1224.
   PubMed Web of Science ®Google Scholar
• Lazo PA, Barcia R. CD53. In: Choi S, editor. Encyclopedia of signaling molecules. New York (NY): Springer; 2012. p. 343–347.
   Google Scholar
• Herman SE, Mustafa RZ, Gyamfi JA, et al. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286–3295.
   PubMed Web of Science ®Google Scholar
• Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008;111:846–855.
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–6296.
   PubMed Web of Science ®Google Scholar
• Lu K, Fang XS, Feng LL, et al. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6. Cancer Lett. 2015;359:250–258.
   PubMed Web of Science ®Google Scholar
• Drucker I, Klajman A, Revel M, et al. Interleukin-6 and interleukin-6 receptor secretion by chronic lymphatic leukaemia and normal B lymphocytes: effect of PMA and PWM. Mediators Inflamm. 1997;6:147–153.
   PubMed Web of Science ®Google Scholar
• Antosz H, Wojciechowska K, Sajewicz J, et al. IL-6, IL-10, c-Jun and STAT3 expression in B-CLL. Blood Cells Mol Dis. 2015;54:258–265.
   PubMed Web of Science ®Google Scholar
• Levidou G, Sachanas S, Pangalis GA, et al. Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance. Biomed Res Int. 2014;2014:251479.
   PubMedGoogle Scholar